Effect of renal denervation on kidney function in patients with chronic kidney disease

Dagmara Hering, Petra Marusic, Jacqueline Duval, Yusuke Sata, Geoffrey A Head, Kate M Denton, Sally Burrows, Antony S Walton, Murray D Esler, Markus P Schlaich

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Aims: Renal denervation (RDN) can reduce blood pressure (BP) and slow the decline of renal function in chronic kidney disease (CKD) up to one year. Whether this effect is maintained beyond 12. months and whether the magnitude of BP reduction affects estimated glomerular filtration rate (eGFR) is unknown. Methods and results: We examined eGFR in 46 CKD patients (baseline eGFR ≤60mL/min/1.73m2) on a yearly basis from 60months before to 3, 6, 12 and 24months after RDN. Ambulatory BP was measured before and after RDN. Linear mixed models analysis demonstrated a significant progressive decline in eGFR from months 60 to 12months (-15.47±1.98mL/min/1.73m2, P<0.0001) and from 12months to baseline prior to RDN (-3.41±1.64mL/min/1.73m2, P=0.038). Compared to baseline, RDN was associated with improved eGFR at 3months (+3.73±1.64mL/min/1.73m2, P=0.02) and no significant changes at 6 (+2.54±1.66mL/min/1.73m2, P=0.13), 12 (+1.78±1.64mL/min/1.73m2, P=0.28), and 24 (-0.24±2.24mL/min/1.73m2, P=0.91) months post procedure were observed. RDN significantly reduced daytime SBP from baseline to 24months post procedure (148±19 vs 136±17mmHg, P=0.03) for the entire cohort. Changes in SBP were unrelated to the eGFR changes at 6 (r=0.033, P=0.84), 12 (r=0.01, P=0.93) and 24months (r=-0.42, P=0.17) follow-up. Conclusion: RDN can slow further deterioration of renal function irrespective of BP lowering effects in CKD. RDN-induced inhibition of sympathetic outflow to the renal vascular bed may account for improved eGFR via alterations of intrarenal and glomerular hemodynamics.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalInternational Journal of Cardiology
Volume232
DOIs
Publication statusPublished - 1 Apr 2017

Keywords

  • Blood pressure
  • Chronic kidney disease
  • Renal denervation
  • Renal function

Cite this

Hering, Dagmara ; Marusic, Petra ; Duval, Jacqueline ; Sata, Yusuke ; Head, Geoffrey A ; Denton, Kate M ; Burrows, Sally ; Walton, Antony S ; Esler, Murray D ; Schlaich, Markus P. / Effect of renal denervation on kidney function in patients with chronic kidney disease. In: International Journal of Cardiology. 2017 ; Vol. 232. pp. 93-97.
@article{67e8b28f63f04c83914639dcb2470f6c,
title = "Effect of renal denervation on kidney function in patients with chronic kidney disease",
abstract = "Aims: Renal denervation (RDN) can reduce blood pressure (BP) and slow the decline of renal function in chronic kidney disease (CKD) up to one year. Whether this effect is maintained beyond 12. months and whether the magnitude of BP reduction affects estimated glomerular filtration rate (eGFR) is unknown. Methods and results: We examined eGFR in 46 CKD patients (baseline eGFR ≤60mL/min/1.73m2) on a yearly basis from 60months before to 3, 6, 12 and 24months after RDN. Ambulatory BP was measured before and after RDN. Linear mixed models analysis demonstrated a significant progressive decline in eGFR from months 60 to 12months (-15.47±1.98mL/min/1.73m2, P<0.0001) and from 12months to baseline prior to RDN (-3.41±1.64mL/min/1.73m2, P=0.038). Compared to baseline, RDN was associated with improved eGFR at 3months (+3.73±1.64mL/min/1.73m2, P=0.02) and no significant changes at 6 (+2.54±1.66mL/min/1.73m2, P=0.13), 12 (+1.78±1.64mL/min/1.73m2, P=0.28), and 24 (-0.24±2.24mL/min/1.73m2, P=0.91) months post procedure were observed. RDN significantly reduced daytime SBP from baseline to 24months post procedure (148±19 vs 136±17mmHg, P=0.03) for the entire cohort. Changes in SBP were unrelated to the eGFR changes at 6 (r=0.033, P=0.84), 12 (r=0.01, P=0.93) and 24months (r=-0.42, P=0.17) follow-up. Conclusion: RDN can slow further deterioration of renal function irrespective of BP lowering effects in CKD. RDN-induced inhibition of sympathetic outflow to the renal vascular bed may account for improved eGFR via alterations of intrarenal and glomerular hemodynamics.",
keywords = "Blood pressure, Chronic kidney disease, Renal denervation, Renal function",
author = "Dagmara Hering and Petra Marusic and Jacqueline Duval and Yusuke Sata and Head, {Geoffrey A} and Denton, {Kate M} and Sally Burrows and Walton, {Antony S} and Esler, {Murray D} and Schlaich, {Markus P}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.ijcard.2017.01.047",
language = "English",
volume = "232",
pages = "93--97",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier",

}

Effect of renal denervation on kidney function in patients with chronic kidney disease. / Hering, Dagmara; Marusic, Petra; Duval, Jacqueline; Sata, Yusuke; Head, Geoffrey A; Denton, Kate M; Burrows, Sally; Walton, Antony S; Esler, Murray D; Schlaich, Markus P.

In: International Journal of Cardiology, Vol. 232, 01.04.2017, p. 93-97.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effect of renal denervation on kidney function in patients with chronic kidney disease

AU - Hering, Dagmara

AU - Marusic, Petra

AU - Duval, Jacqueline

AU - Sata, Yusuke

AU - Head, Geoffrey A

AU - Denton, Kate M

AU - Burrows, Sally

AU - Walton, Antony S

AU - Esler, Murray D

AU - Schlaich, Markus P

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Aims: Renal denervation (RDN) can reduce blood pressure (BP) and slow the decline of renal function in chronic kidney disease (CKD) up to one year. Whether this effect is maintained beyond 12. months and whether the magnitude of BP reduction affects estimated glomerular filtration rate (eGFR) is unknown. Methods and results: We examined eGFR in 46 CKD patients (baseline eGFR ≤60mL/min/1.73m2) on a yearly basis from 60months before to 3, 6, 12 and 24months after RDN. Ambulatory BP was measured before and after RDN. Linear mixed models analysis demonstrated a significant progressive decline in eGFR from months 60 to 12months (-15.47±1.98mL/min/1.73m2, P<0.0001) and from 12months to baseline prior to RDN (-3.41±1.64mL/min/1.73m2, P=0.038). Compared to baseline, RDN was associated with improved eGFR at 3months (+3.73±1.64mL/min/1.73m2, P=0.02) and no significant changes at 6 (+2.54±1.66mL/min/1.73m2, P=0.13), 12 (+1.78±1.64mL/min/1.73m2, P=0.28), and 24 (-0.24±2.24mL/min/1.73m2, P=0.91) months post procedure were observed. RDN significantly reduced daytime SBP from baseline to 24months post procedure (148±19 vs 136±17mmHg, P=0.03) for the entire cohort. Changes in SBP were unrelated to the eGFR changes at 6 (r=0.033, P=0.84), 12 (r=0.01, P=0.93) and 24months (r=-0.42, P=0.17) follow-up. Conclusion: RDN can slow further deterioration of renal function irrespective of BP lowering effects in CKD. RDN-induced inhibition of sympathetic outflow to the renal vascular bed may account for improved eGFR via alterations of intrarenal and glomerular hemodynamics.

AB - Aims: Renal denervation (RDN) can reduce blood pressure (BP) and slow the decline of renal function in chronic kidney disease (CKD) up to one year. Whether this effect is maintained beyond 12. months and whether the magnitude of BP reduction affects estimated glomerular filtration rate (eGFR) is unknown. Methods and results: We examined eGFR in 46 CKD patients (baseline eGFR ≤60mL/min/1.73m2) on a yearly basis from 60months before to 3, 6, 12 and 24months after RDN. Ambulatory BP was measured before and after RDN. Linear mixed models analysis demonstrated a significant progressive decline in eGFR from months 60 to 12months (-15.47±1.98mL/min/1.73m2, P<0.0001) and from 12months to baseline prior to RDN (-3.41±1.64mL/min/1.73m2, P=0.038). Compared to baseline, RDN was associated with improved eGFR at 3months (+3.73±1.64mL/min/1.73m2, P=0.02) and no significant changes at 6 (+2.54±1.66mL/min/1.73m2, P=0.13), 12 (+1.78±1.64mL/min/1.73m2, P=0.28), and 24 (-0.24±2.24mL/min/1.73m2, P=0.91) months post procedure were observed. RDN significantly reduced daytime SBP from baseline to 24months post procedure (148±19 vs 136±17mmHg, P=0.03) for the entire cohort. Changes in SBP were unrelated to the eGFR changes at 6 (r=0.033, P=0.84), 12 (r=0.01, P=0.93) and 24months (r=-0.42, P=0.17) follow-up. Conclusion: RDN can slow further deterioration of renal function irrespective of BP lowering effects in CKD. RDN-induced inhibition of sympathetic outflow to the renal vascular bed may account for improved eGFR via alterations of intrarenal and glomerular hemodynamics.

KW - Blood pressure

KW - Chronic kidney disease

KW - Renal denervation

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=85009739535&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2017.01.047

DO - 10.1016/j.ijcard.2017.01.047

M3 - Article

VL - 232

SP - 93

EP - 97

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -